Position for success: Differentiate your oncology drug with Clario

In oncology, similar efficacy levels across drugs mean that quality of life (QoL) impact becomes the key differentiator. Does your drug have a robust patient-reported outcomes (PRO) strategy to meet regulatory expectations and truly stand out? Get the insights to make your mark.

Inside the guide:

5 key insights on how your PRO strategy can differentiate your drug

PROs on the rise

Understand why 13 oncology drugs added PRO data to their labels since 2012, and its distinct advantage.

Regulatory emphasis on patient quality of life

Grasp the FDA’s 2020 Project Patient Voice and its focus on patients’ lived experiences.

Customized questionnaires

Learn how tailored symptom-based questions directly link to enhanced quality of life.

Symptom capture

See the significance of patient feedback between site visits for a holistic drug impact assessment.

eCOA strategy from the start

Realize the importance of initiating your PRO approach early, prepping for a concrete Phase III strategy.